CN108752255A - A kind of preparation method of pabishta and its key intermediate - Google Patents
A kind of preparation method of pabishta and its key intermediate Download PDFInfo
- Publication number
- CN108752255A CN108752255A CN201810798093.5A CN201810798093A CN108752255A CN 108752255 A CN108752255 A CN 108752255A CN 201810798093 A CN201810798093 A CN 201810798093A CN 108752255 A CN108752255 A CN 108752255A
- Authority
- CN
- China
- Prior art keywords
- methyl
- preparation
- benzaldehydes
- formula
- pabishta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HKOOXMFOFWEVGF-UHFFFAOYSA-N NNc1ccccc1 Chemical compound NNc1ccccc1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
The invention belongs to pharmaceutical synthesis fields, more particularly to a kind of pabishta and its preparation method of key intermediate, the method is with inexpensive 4- halogenated methyl-benzaldehydes, 2- methyltryptamines and phosphine acyl acetic acid first ester type compound are raw material, it treats different things alike to obtain key intermediate (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate, pabishta is made with azanol reaction again, not only raw material is cheap and easy to get for the method, it is of low cost, and reaction step is few, yield and purity are high, simultaneous reactions mild condition, it is easy to operate, it is easy to industrialized production.
Description
Technical field
The invention belongs to pharmaceutical synthesis fields, and in particular to a kind of pabishta and its preparation method of key intermediate.
Background technology
Pabishta (panobinostat), chemical name are N- hydroxyls -3- [4- [[[2- (2- Methyl-1H-indoles -3-
Base)-ethyl]-amino] methyl] phenyl] -2E-2- acrylamides, chemical constitution is the one of Novartis Co., Ltd's exploitation as shown in formula A
Kind hydroxamic acid micromolecular histone deacetylase enzyme (HDAC) inhibitor, 2 U.S. Yue23Huo food in 2015 and drug prison
Pipe office (FDA) approval listing, is used for the treatment of Huppert's disease, early stage acute myeloid leukaemia, which may delay more
The excessive generation of thick liquid cell in hair property patients with malignant myeloma body, or lead to these dangerous cell deaths,
Currently, the synthetic method of the pabishta of document report mainly has 2 kinds, the first is Novartis Co., Ltd in the patent world
Apply for pabishta compound and preparation method thereof, two documents disclosed in WO02/22577A2 and WO2007/146718 A2
Disclosed method is all to obtain pa with azanol reaction again after reaction using 2- methyltryptamines and 4- formyls-methyl cinnamate as raw material
Than department he, reaction route is as follows：
Intermediate 4- formyls-methyl cinnamate that the above method is used is expensive, and yield and purity is not high, is unfavorable for
The quality control of pabishta bulk pharmaceutical chemicals and reduce cost.
Be for second Liu Qian etc. (《Chinese Journal of Pharmaceuticals》, 2011,42 (10), p725-727) disclosed in a kind of pa ratio
His synthetic method is taken charge of, this method is using (E) -4- methyl cinnamic acids methyl esters as raw material, in carbon tetrachloride solvent after NBS bromos,
(E) -3- [4- [[2- (2- Methyl-1H-indole -3- bases) ethylamino-] methyl] phenyl] acrylic acid is obtained by the reaction with 2- methyltryptamines
Methyl ester hydrochloride, then pabishta is obtained with azanol reaction, reaction route is as follows：
The above method is not only needed using hypertoxic solvent carbon tetrachloride, and also needs in Suzuki coupling reactions to use costliness
Heavy metal catalyst palladium, simultaneous reactions temperature is high, and reaction condition is violent, and yield is not high, is unfavorable for pabishta raw material
The quality control of medicine and reduce cost.
No matter which kind of route, be required for synthesis key intermediate (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases)
Ethylamino-] methyl] phenyl] methyl acrylate (structure is as shown in formula III), therefore, exploration one is cheap and easy to get, easy to operate,
Reaction condition is mild, environmental-friendly, it is easy to accomplish the synthetic method of the pabishta key intermediate of industrialized production, to reducing
Pabishta bulk pharmaceutical chemicals cost and raising pabishta bulk pharmaceutical chemicals quality have great importance.
Invention content
It is an object of the present invention to provide a kind of pabishta key intermediate (E) -3- [4- [[2- (2- methyl-1s H-
Indoles -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate preparation method, the method is with inexpensive 4- halogenated methyl benzene
Formaldehyde (structure is shown in formula I), 2- methyltryptamines and phosphine acyl acetic acid first ester type compound (structure is as shown in Formula II) are raw material,
It treats different things alike and can be obtained, not only raw material is cheap and easy to get for the method, of low cost, and reaction step is few, and yield and purity are high, together
When reaction condition it is mild, it is easy to operate, be easy to industrialized production.
It is a further object to provide a kind of preparation method of pabishta, the method is halogenated with inexpensive 4-
Tolyl aldehyde (structure is shown in formula I), 2- methyltryptamines and phosphine acyl acetic acid first ester type compound (structure is as shown in Formula II)
For raw material, obtained (the E) -3- that treats different things alike [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] acrylic acid first
After ester, then with azanol reaction pabishta is made, the method is of low cost, and yield and purity are high, and reaction condition is mild, operation
Simplicity is easy to industrialized production.
For achieving the above object, the present invention provides following technical scheme：
In a first aspect, a kind of pabishta intermediate (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-]
Methyl] phenyl] methyl acrylate preparation method, including：0 DEG C~at room temperature, and under the catalysis of DBU, 4- halogen shown in formula (I)
It is reacted for phosphine acyl acetic acid first ester type compound shown in tolyl aldehyde, 2- methyltryptamines and formula (II), formula (III) institute is made
Show that compound, reaction equation are as follows：
In formula, X is halogen, R1、R2Independently selected from hydrogen and alkyl；Preferably, X is selected from chlorine and bromine, R1、R2Independently select
From hydrogen, methyl, ethyl and isopropyl.
A kind of second aspect, preparation method of pabishta, includes the following steps：
Step (1)：0 DEG C~at room temperature, and under the catalysis of DBU, 4- halogenated methyl-benzaldehydes, 2- methyl shown in formula (I)
Phosphine acyl acetic acid first ester type compound shown in tryptamines and formula (II) reacts, and compound shown in formula (III) is made,；
Step (2)：Pabishta is made with azanol reaction in compound shown in formula (III), and reaction equation is as follows,
In formula, X is halogen, R1、R2Independently selected from hydrogen and alkyl；Preferably, X is selected from chlorine and bromine, R1、R2Independently select
From hydrogen, methyl, ethyl and isopropyl.
According to the present invention, the 4- halogenated methyl-benzaldehydes, 2- methyltryptamines and phosphine acyl acetic acid first ester type compound are anti-
The solvent answered is DMF.The inventors discovered that reaction dissolvent is very big on the influence of the yield of target compound, when use acetonitrile, acetic acid
When the organic solvents such as ethyl ester, dichloromethane, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran are reaction dissolvent, it cannot get target chemical combination at all
Object or target compound yield are relatively low, and impurity is more, when being only solvent with DMF, can obtain high yield, the target of high-purity
Compound.
According to the present invention, the 4- halogenated methyl-benzaldehydes, 2- methyltryptamines and phosphine acyl acetic acid first ester type compound are anti-
The temperature answered is 0 DEG C~10 DEG C.
According to the present invention, the molar ratio of the 4- halogenated methyl-benzaldehydes and 2- methyltryptamines is 1~1.5:1；Preferably,
The molar ratio of the 4- halogenated methyl-benzaldehydes and 2- methyltryptamines is 1~1.2:1.
According to the present invention, the molar ratio of the 4- halogenated methyl-benzaldehydes and phosphine acyl acetic acid first ester type compound is 1:2
~3；Preferably, the molar ratio of the 4- halogenated methyl-benzaldehydes and phosphine acyl acetic acid first ester type compound is 1:2.5.
According to the present invention, the 4- halogenated methyl-benzaldehydes, 2- methyltryptamines and phosphine acyl acetic acid first ester type compound are anti-
The seasonable lithium chloride that is added is catalyst.
Specific embodiment
The preparation of 1 2- methyltryptamines of embodiment
Phenylhydrazine (19.8ml, 200mmol), absolute ethyl alcohol (120ml) are added in 500ml there-necked flasks, are heated to 35 DEG C, N2
The ethanol solution (25ml) of the chloro- 2 pentanones of 5- (25ml, 210mmol) is added dropwise in protection, is added after being warming up to 40 DEG C of reaction 30min
Ethyl alcohol 160ml is to slowly warm up to back flow reaction 4h, and solvent is spin-dried for after suction filtration, and water (50ml) is added to use 2M hydrochloric acid solution tune Ph to acid afterwards
Property, ethyl acetate (50ml*2) extraction discards organic phase, water phase 20%NaOH solution tune pH to alkalinity, ethyl acetate
(50ml*2) is extracted, and merges organic phase, is washed respectively with water (50ml*2) and saturation chlorinated solution (50ml*2), anhydrous sodium sulfate
It is filtered after drying, is spin-dried for obtaining red oil 24.2g, yield 70.1%.
Embodiment 2 (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate
Preparation
Take 2- methyltryptamines (1.4g, 8mmol), DMF (10ml), DBU (3.8g, 25mmol), lithium chloride (0.04g,
1mmol), phosphonium mesitoyl methyl acetate diethyl (5.2g, 25mmol) is in 50ml single port bottles, N2Protection, 0 DEG C of stirring 15min, drop
Add DMF (5ml) solution of 4- chloromethylbenzenes formaldehyde (1.5g, 10mmol), equality of temperature to react 6h, water 50ml, ethyl acetate is added
(50ml*3) is extracted, and merges organic phase, and water 50ml, saturated nacl aqueous solution (50ml*2) washing, anhydrous sodium sulfate is used to do respectively
Filtered after dry, be spin-dried for solvent, ethyl acetate dissolving is added, Isosorbide-5-Nitrae-dioxane/HCl solution to acidity is added dropwise, filter class is white
Color solid 1.5g, yield 50%.
1H NMR(600MHz,DMSO-d6)(δ,ppm):2.34(s,3H),2.92(m,2H),3.17(m,2H),3.74(s,
3H),4.21(t,2H),6.72(d,1H),7.01(m,2H),7.25(d,1H),7.46(d,1H),7.65(d,2H),7.69(d,
1H),7.80(d,2H),9.59(brs,2H),10.90(s,1H)；13C NMR(150MHz,DMSO-d6)(δ,ppm):11.6,
21.0,47.4,49.8,52.0,66.8,105.6,111.0,117.6,118.7,119.0,120.6,128.2,128.9,
130.9,133.1,134.9,135.6,144.2,167.0。
ESI–MS:m/z 349.0[M+H]+。
Embodiment 3 (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate
Preparation
Take 2- methyltryptamines (1.4g, 8mmol), DMF (10ml), DBU (3.8g, 25mmol), lithium chloride (0.04g,
1mmol), phosphonium mesitoyl methyl acetate diethyl (4.2g, 20mmol) is in 50ml single port bottles, N2Protection, 0 DEG C of stirring 15min, drop
Add DMF (5ml) solution of 4- chloromethylbenzenes formaldehyde (1.5g, 10mmol), equality of temperature to react 6h, water 50ml, ethyl acetate is added
(50ml*3) is extracted, and merges organic phase, and water 50ml, saturated nacl aqueous solution (50ml*2) washing, anhydrous sodium sulfate is used to do respectively
Filtered after dry, be spin-dried for solvent, ethyl acetate dissolving is added, Isosorbide-5-Nitrae-dioxane/HCl solution to acidity is added dropwise, filter class is white
Color solid 1.35g, yield 45%.
Embodiment 4 (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate
Preparation
Take 2- methyltryptamines (1.2g, 6.7mmol), DMF (10ml), DBU (3.8g, 25mmol), lithium chloride (0.04g,
1mmol), phosphonium mesitoyl methyl acetate diethyl (4.2g, 20mmol) is in 50ml single port bottles, N2Protection, 0 DEG C of stirring 15min, drop
Add DMF (5ml) solution of 4- chloromethylbenzenes formaldehyde (1.5g, 10mmol), equality of temperature to react 6h, water 50ml, ethyl acetate is added
(50ml*3) is extracted, and merges organic phase, and water 50ml, saturated nacl aqueous solution (50ml*2) washing, anhydrous sodium sulfate is used to do respectively
Filtered after dry, be spin-dried for solvent, ethyl acetate dissolving is added, Isosorbide-5-Nitrae-dioxane/HCl solution to acidity is added dropwise, filter class is white
Color solid 1.65g, yield 55%.
Embodiment 5 (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl] methyl acrylate
Preparation
Take 2- methyltryptamines (1.75g, 10mmol), DMF (10ml), DBU (3.8g, 25mmol), lithium chloride (0.04g,
1mmol), phosphonium mesitoyl methyl acetate diethyl (6.3g, 30mmol) is in 50ml single port bottles, N2Protection, 0 DEG C of stirring 15min, drop
Add DMF (5ml) solution of 4- chloromethylbenzenes formaldehyde (1.5g, 10mmol), equality of temperature to react 6h, water 50ml, ethyl acetate is added
(50ml*3) is extracted, and merges organic phase, and water 50ml, saturated nacl aqueous solution (50ml*2) washing, anhydrous sodium sulfate is used to do respectively
Filtered after dry, be spin-dried for solvent, ethyl acetate dissolving is added, Isosorbide-5-Nitrae-dioxane/HCl solution to acidity is added dropwise, filter class is white
Color solid 1.47g, yield 49%.
The preparation of 6 pabishta of embodiment
By (2E) -3- (4- (((2- (2- Methyl-1H-indole -3- bases) ethyl) amino) methyl) phenyl) -2- acrylic acid first
Ester (0.48g, 1.4mmol) is placed in 50ml single port bottles, and the KOH solution (8.2ml, 14mmol) of azanol methanol, N is added2Protection, room
Temperature reaction 6h is filtered with dilute hydrochloric acid solution tune pH 7-8, and filter cake is washed with water, dry off-white powder 0.3g, yield
62.5%.
1H NMR(600MHz,DMSO-d6)(δ,ppm):2.31(s,3H),2.69(t,2H),2.81(t,2H),3.77(s,
2H),6.45(d,1H),6.90(m,1H),6.95(m,1H),7.22(d,1H),7.38(m,3H),7.44(d,1H),7.49(d,
2H),10.70(brs,1H).；13C NMR(150MHz,CDCl3)(δ,ppm):11.7,24.7,50.0,52.8,108.5,
110.8,117.8,118.4,118.8,120.3,127.7,128.8,128.9,132.2,133.6,135.6,138.6,
142.7,163.2。
ESI–MS:m/z 350.0[M+H]+。
Claims (9)
1. a kind of pabishta intermediate (E) -3- [4- [[2- (2- Methyl-1H-indole -3-3 bases) ethylamino-] methyl] phenyl]
The preparation method of methyl acrylate, including：0 DEG C~at room temperature, and under the catalysis of DBU, 4- halogenated methyls benzene first shown in formula (I)
Phosphine acyl acetic acid first ester type compound reacts to obtain the final product shown in aldehyde, 2- methyltryptamines and formula (II), and reaction equation is as follows：
In formula, X is halogen, R1、R2Independently selected from hydrogen and alkyl；Preferably, X is selected from chlorine and bromine, R1、R2Independently selected from hydrogen,
Methyl, ethyl and isopropyl.
2. a kind of preparation method of pabishta, includes the following steps：
Step (1)：0 DEG C~at room temperature, and under the catalysis of DBU, 4- halogenated methyl-benzaldehydes, 2- methyltryptamines shown in formula (I)
It is reacted with phosphine acyl acetic acid first ester type compound shown in formula (II), compound shown in formula (III) is made；
Step (2)：Pabishta is made with azanol reaction in compound shown in formula (III), and reaction equation is as follows,
In formula, X is halogen, R1、R2Independently selected from hydrogen and alkyl；Preferably, X is selected from chlorine and bromine, R1、R2Independently selected from hydrogen,
Methyl, ethyl and isopropyl.
3. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes, 2- methyltryptamines
Solvent with the reaction of phosphine acyl acetic acid first ester type compound is DMF.
4. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes, 2- methyltryptamines
Temperature with the reaction of phosphine acyl acetic acid first ester type compound is 0 DEG C~10 DEG C.
5. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes and 2- methyl colors
The molar ratio of amine is 1~1.5:1.
6. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes and 2- methyl colors
The molar ratio of amine is 1.25:1.
7. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes and phosphono second
The molar ratio of sour first ester type compound is 1:2~3.
8. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes and phosphono second
The molar ratio of sour first ester type compound is 1:2.5.
9. preparation method as claimed in claim 1 or 2, it is characterised in that：The 4- halogenated methyl-benzaldehydes, 2- methyltryptamines
It is catalyst that lithium chloride is added when being reacted with phosphine acyl acetic acid first ester type compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810798093.5A CN108752255A (en) | 2018-07-19 | 2018-07-19 | A kind of preparation method of pabishta and its key intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810798093.5A CN108752255A (en) | 2018-07-19 | 2018-07-19 | A kind of preparation method of pabishta and its key intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108752255A true CN108752255A (en) | 2018-11-06 |
Family
ID=63970615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810798093.5A Pending CN108752255A (en) | 2018-07-19 | 2018-07-19 | A kind of preparation method of pabishta and its key intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108752255A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030018062A1 (en) * | 2000-09-01 | 2003-01-23 | Remiszewski Stacy W. | Deacetylase inhibitors |
| CN101684088A (en) * | 2008-09-22 | 2010-03-31 | 天津药物研究院 | Cyanomethyl pyrrole derivative and preparation method and application thereof |
| CN106674079A (en) * | 2015-11-10 | 2017-05-17 | 南京卡文迪许生物工程技术有限公司 | Synthesis method of panobinostat |
-
2018
- 2018-07-19 CN CN201810798093.5A patent/CN108752255A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030018062A1 (en) * | 2000-09-01 | 2003-01-23 | Remiszewski Stacy W. | Deacetylase inhibitors |
| CN1450991A (en) * | 2000-09-01 | 2003-10-22 | 诺瓦提斯公司 | Hydroxamate derives useful as deacetylase inhibitors |
| CN101684088A (en) * | 2008-09-22 | 2010-03-31 | 天津药物研究院 | Cyanomethyl pyrrole derivative and preparation method and application thereof |
| CN106674079A (en) * | 2015-11-10 | 2017-05-17 | 南京卡文迪许生物工程技术有限公司 | Synthesis method of panobinostat |
Non-Patent Citations (4)
| Title |
|---|
| KAORI ANDO ET AL.: "Solvent-free Horner-Wadsworth Emmons reaction using DBU", 《TETRAHEDRON LETTERS》 * |
| MANKIL JUNG ET AL.: "Design, synthesis, and discovery of stilbene derivatives based on lithospermic acid B as potent protein tyrosine phosphatase 1B inhibitors", 《BIOORG. MED. CHEM. LETT.》 * |
| 刘倩等: "帕比司他的合成", 《中国医药工业杂志》 * |
| 卡拉瑟斯等: "《当代有机合成方法》", 31 March 2006, 华东理工大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103524440B (en) | The preparation method of gout therapertics Lesinurad and Lesinurad intermediate | |
| CN104610250A (en) | 1,2,3-thiadiazole-5-formamidine compound containing three N-heterocycles and synthesis | |
| CN104945299B (en) | A kind of high-efficiency synthesis method of vildagliptin | |
| CN105085373B (en) | A kind of purification process to Apremilast product | |
| US7332614B2 (en) | Process for cross coupling indoles | |
| CN104530040A (en) | Novel method for synthesizing 1,2,3-thiadiazole-5-formamidine compound | |
| CN104530033B (en) | A kind of preparation technology new method of Arotinolol Hydrochlorid | |
| CN112062712A (en) | Preparation method of 2- (5-bromo-3-methylpyridin-2-yl) acetic acid hydrochloride | |
| CN108794375A (en) | A kind of pabishta intermediate and its synthesis and application | |
| CN108752255A (en) | A kind of preparation method of pabishta and its key intermediate | |
| CN101391943B (en) | Method for preparing 4-chlorophenylcyclopropyl methyl ketone | |
| CN106957237B (en) | A method of synthesis bromfenac sodium | |
| CN106588921B (en) | A kind of synthetic method of the methyl formate of 7 azaindole 3 | |
| CN104136422B (en) | The process for purification of compound, the manufacture method of compound and compound | |
| CN105272921A (en) | Method for preparing Ceritinib and intermediate compound of Ceritinib | |
| CN105439966B (en) | Compound and its preparation method and application | |
| CN107033039B (en) | A kind of synthetic method of his key intermediate of anti-tumor drug Baily department | |
| CN103193699B (en) | Novel method for preparing prucalopride intermediate | |
| CN103539794A (en) | Salifying method of lurasidone hydrochloride | |
| CN105906607A (en) | Dabigatran etexilate synthesis method | |
| CN104610133A (en) | Method for synthesizing novel anticancer medicine entinostat | |
| CN106467500A (en) | A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate | |
| CN109384680A (en) | A kind of preparation method of flibanserin intermediate | |
| CN108395415A (en) | A method of preparing 1- (3- bromopropyls) -1,4- phenodiazine cycloheptane hydrobromates | |
| CN112661671B (en) | Preparation method of Sacubitril intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181106 |
|
| WD01 | Invention patent application deemed withdrawn after publication |